Coleman, Jonathan R. I. http://orcid.org/0000-0002-6759-0944
Bryois, Julien http://orcid.org/0000-0002-4747-2166
Gaspar, Héléna A. http://orcid.org/0000-0002-5540-2707
Jansen, Philip R.
Savage, Jeanne E. http://orcid.org/0000-0002-2034-8341
Skene, Nathan
Plomin, Robert
Muñoz-Manchado, Ana B.
Linnarsson, Sten http://orcid.org/0000-0002-3491-3444
Crawford, Greg
Hjerling-Leffler, Jens http://orcid.org/0000-0002-4539-1776
Sullivan, Patrick F.
Posthuma, Danielle http://orcid.org/0000-0001-7582-2365
Breen, Gerome http://orcid.org/0000-0003-2053-1792
Article History
Received: 18 August 2017
Revised: 13 November 2017
Accepted: 2 January 2018
First Online: 8 March 2018
Compliance with ethical standards
:
: PFS reports the following potentially competing financial interests: Lundbeck (advisory committee), Pfizer (Scientific Advisory Board member), and Roche (grant recipient, speaker reimbursement). GB reports consultancy and speaker fees from Eli Lilly and Illumina and grant funding from Eli Lilly. All remaining authors declare that they have no conflict of interest.